Why Is Foghorn Therapeutics (FHTX) Stock Down -14.38% Today?
Key Takeaways
- Shares of FHTX fell roughly 14.4% on Friday, extending the steep decline that began after Thursday's announcement ending its collaboration with Eli Lilly.
- Primary catalyst: Foghorn and Eli Lilly elected not to advance the cancer candidate FHD-909 into the next phase of testing and ended a second joint program, effectively terminating the partnership.
- Cost restructuring: The company disclosed plans to cut approximately 40% of its workforce to extend its cash runway into the second half of 2029.
- Wall Street reaction: Multiple analysts downgraded the stock, with several citing the loss of its only clinical-stage asset.
- What to watch next: Investors are monitoring pipeline reprioritization, headcount reductions, and any further analyst revisions.
Opening Summary
Foghorn Therapeutics Inc. (FHTX) is a clinical-stage precision therapeutics biotechnology company that develops medicines targeting dependencies within the chromatin regulatory system, using its proprietary Gene Traffic Control platform. On Friday, the stock was down about 14.4%, trading near $2.50, after closing the prior session at $2.92. The decline is a continuation of the sharp sell-off triggered by Thursday's announcement that the company and partner Eli Lilly (LLY) are ending their cancer drug collaboration, a setback that is forcing Foghorn to restructure its operations.
End of the Eli Lilly Collaboration
The dominant driver of the move is the dissolution of Foghorn's development partnership with Eli Lilly. Following a review of Phase 1 dose-escalation data, the companies decided not to advance FHD-909 (LY4050784), a first-in-class, orally available SMARCA2 inhibitor, into the clinical development expansion phase. The companies also chose not to advance a separate selective SMARCA2 degrader program and stated that they do not anticipate further collaboration activities.
Foghorn's CEO noted that while the drug demonstrated a favorable safety profile and selectively hit its SMARCA2 target, the biology of the SMARCA2/4 synthetic lethality relationship "has not translated into the level of efficacy required to further advance the program." The loss of FHD-909, the company's only clinical-stage asset, removes a central pillar of the investment thesis and explains the sustained pressure on the share price.
Workforce Reduction and Pipeline Reprioritization
In response to the setback, Foghorn said it will reduce its workforce by approximately 40%, a move expected to leave the company with roughly 65 employees compared with 106 at the end of 2025. The company anticipates recording about $2.3 million in charges tied to the layoffs, which are expected to be completed in the fourth quarter.
The restructuring is designed to conserve cash and refocus resources on the company's wholly owned pipeline, including a selective EP300 degrader program, a novel oral immunology and inflammation program, a selective CBP degrader program, and its induced proximity platform. Foghorn reported $167.6 million in cash as of June 30, 2026, and said the cost-cutting measures should fund its priority programs into the second half of 2029.
Analyst Downgrades and Price-Target Cuts
The negative news triggered a wave of analyst revisions that compounded the selling pressure. Wedbush downgraded the stock to Neutral from Outperform and slashed its price target to $2 from $10, stating that the collaboration had been the primary driver of its bullish thesis. Citizens moved to Market Perform from Market Outperform, while TD Cowen and BTIG each shifted to a Hold/Neutral stance, citing the loss of the company's only clinical-stage asset and the early stage of the remaining pipeline. HC Wainwright maintained a Buy rating but lowered its price target to $5 from $13.
Market Context and Trading Activity
The price action reflects a genuine repricing of the stock rather than broad market weakness. Trading volume on Thursday surged to more than 8.3 million shares, well above Foghorn's typical daily average of roughly a few hundred thousand shares, underscoring heavy institutional repositioning following the announcement. The decline has been company-specific: while broader biotech indices and large-cap pharmaceuticals showed only modest moves, FHTX fell sharply as investors recalibrated expectations for a pipeline now centered on preclinical programs.
What Comes Next for FHTX
Looking ahead, the focus shifts to execution of the pipeline reprioritization and the completion of the workforce reduction. Key milestones include the company's stated goal of filing an Investigational New Drug application for its EP300 degrader program in 2027, with an initial focus on multiple myeloma and diffuse large B-cell lymphoma. Risks remain substantial: with no clinical-stage asset, the company may need additional capital or new partnerships to advance its programs, and investor sentiment will hinge on early validation of the remaining candidates. Upcoming earnings updates and further analyst commentary will provide additional signals on the company's cash position and strategic direction.
Trending AI Robots
For traders seeking a data-driven edge across thousands of equities, Tickeron's Trending AI Robots page offers a curated view of its strongest-performing AI trading bots under current market conditions. Tickeron provides hundreds of AI trading bots spanning thousands of tickers, with strategies that differ by approach, timeframe, performance metrics, and traded symbols. Exploring this section can help you discover automated tools aligned with your own trading style.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FHTX's RSI Oscillator stays in oversold zone for 22 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 237 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
FHTX moved below its 50-day moving average on September 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FHTX crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. FHTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: FHTX's P/B Ratio (2000.000) is very high in comparison to the industry average of (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement